BTIG Research Reiterates “Buy” Rating for Monopar Therapeutics (NASDAQ:MNPR)

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a report released on Monday,Benzinga reports. They currently have a $104.00 price objective on the stock. BTIG Research’s price objective would indicate a potential upside of 55.48% from the company’s previous close.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Raymond James Financial downgraded Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their target price for the stock from $142.00 to $123.00 in a research note on Friday, November 14th. Morgan Stanley began coverage on shares of Monopar Therapeutics in a report on Friday, January 9th. They issued an “overweight” rating and a $115.00 target price for the company. Chardan Capital restated a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $107.00.

Monopar Therapeutics Trading Up 2.2%

NASDAQ MNPR opened at $66.89 on Monday. The firm’s 50 day simple moving average is $70.96 and its 200 day simple moving average is $66.06. The firm has a market capitalization of $446.83 million, a price-to-earnings ratio of -19.44 and a beta of 1.52. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.02). On average, equities research analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, CFO Quan Anh Vu purchased 1,500 shares of the firm’s stock in a transaction on Friday, December 26th. The stock was purchased at an average cost of $69.95 per share, for a total transaction of $104,925.00. Following the transaction, the chief financial officer owned 1,500 shares in the company, valued at $104,925. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by insiders.

Institutional Trading of Monopar Therapeutics

Institutional investors have recently modified their holdings of the business. Mountain Pacific Investment Advisers LLC acquired a new stake in Monopar Therapeutics in the fourth quarter valued at $398,000. TCG Crossover Management LLC bought a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at about $12,496,000. Alyeska Investment Group L.P. bought a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at about $998,000. Vivo Capital LLC acquired a new stake in shares of Monopar Therapeutics in the third quarter valued at about $7,391,000. Finally, Ally Bridge Group NY LLC raised its position in shares of Monopar Therapeutics by 86.6% during the third quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after acquiring an additional 29,918 shares during the last quarter. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.